Multiple Organ Failure

Pathophysiology, Prevention, and Therapy

Inbunden, Engelska, 2000

Av Arthur E. Baue, Eugen Faist, Donald Fry

2 879 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This text brings together international experts to explore the pathophysiology, prevention, and treatment of Systemic Inflammatory Response Syndrome, Multiple Organ Dysfunction Syndrome and Multiple Organ Failure with an emphasis on injury, ischemia, and inflammation. Emphasizing material of clinical relevance to patient care, 75 chapters address development of SIRS, MODS and MOF including risk history; mechanisms of SIRS and organ failure; mediators and effectors including cytokines, biologic control of inflammation, histamine, nitric oxide; prevention and general therapy including intensive care monitoring, surgical intervention and operating for trauma; specific remote organ failure including lungs, stomach, kidneys, liver and CNS: and a comprehensive summary of therapeutic horizons. Generously illustrated with more than 300 drawings, photographs and tables, this text is an invaluable resource for general surgeons, critical and intensive care specialists and disease experts.

Produktinformation

Utgivningsdatum2000-06-08
Mått210 x 279 x 44 mm
Vikt2 023 g
FormatInbunden
SpråkEngelska
Antal sidor712
Upplaga2000
FörlagSpringer-Verlag New York Inc.
ISBN9780387987330

Tillhör följande kategorier

Klinisk medicin och internmedicin inom Medicin
Olycksfalls- och akutmedicin inom Medicin
Kirurgi inom Medicin
Patologi inom Medicin

I Development of SIRS, MODS, and MOF.- 1. History of MOF and Definitions of Organ Failure.- 2. SIRS, MODS, and the Brave New World of ICU Acronyms Have They Helped Us?.- 3. Systemic Inflammatory Response and Multiple Organ Dysfunction Syndrome: Biologic Domino Effect.- 4. Risk Factors for MOF and Pattern of Organ Failure Following Severe Trauma.- 5. Risk and Setting for Multiple Organ Failure in Medical Patients.- 6. Epidemiology, Risk Factors, and Outcome of Multiple Organ Dysfunction Syndrome in Surgical Patients.- II Mechanisms of SIRS and Organ Failure.- 7. Systemic Inflammation After Trauma, Infection, and Cardiopulmonary Bypass; Is Autodestruction a Necessary Evil?.- 8. Cardiopulmonary Bypass for Cardiac Surgery;An Inflammatory Event: Can It Be Modulated?.- 9. Gut: Clinical Importance of Bacterial Translocation, Permeability, and Other Factors.- 10. Mcrocirculatory Arrest Theory of SIRS and MODS.- 11. Infection, Bacteremia, Sepsis, and the Sepsis Syndrome: Metabolic Alterations, Hypermetabolism, and Cellular Alterations.- 12. Ischemia and Reperfusion as a Cause of Multiple Organ Failure.- 13. Endotoxin in Human Disease and Its Endogenous Control.- 14. Untimely Apoptosis in Human SIRS, Sepsis, and MODS.- 15. Immunosuppression with Injury and Operation and Increased Susceptibility to Infection.- III Mediators and Effectors.- 16. Emerging Evidence of a More Complex Role for Proinflammatory and Antünflammatory Cytokines in the Sepsis Response.- 17. Counterregulation of Severe Inflammation: When More Is Too Much and Less Is Inadequate.- 18. Reactive Oxygen Species in Clinical Practice.- 19. Nitric Oxide as a Modulator of Sepsis: Therapeutic Possibilities.- 20. Mast Cells.- 21. Eicosanoids.- 22. Platelet-Activating Factor.- 23. Therapeutic Complement Inhibition.- 24.Leukocyte—Endothelial Cell Interactions: Review of Adhesion Molecules and Their Role in Organ Injury.- IV Prevention and General Therapy.- 25. Care of Injured Patients in the Field, During Transport, and in the Emergency Department.- 26. Intensive Care Monitoring.- 27. Peritonitis: Management of The Patient with SIRS and MODS.- 28. Hypothermia—Coagulopathy—Acidosis Syndrome: When to Operate/When to Stop Operating.- 29. Early Definitive Fracture Fixation with Polytrauma: Advantages Versus Systemic/Pulmonary Consequences.- 30. Abdominal Compartment Syndrome.- 31. SIRS and MODS: Indications for Surgical Intervention?.- 32. Nosocomial Infections in the ICU.- 33. Modulation of the Hypermetabolic Response After Trauma and Burns.- V Specific Remote Organ Failures.- 34. Circulation.- 35. Effect of Inflammatory Conditions on the Heart.- 36. Lung.- 37. Renal Function and Dysfunction in Multiple Organ Failure.- 38. Metabolic Depletion and Failure: Muscle Cachexia During Injury and Sepsis.- 39. Immunomodulation of Cell-Mediated Responses: Is It Feasible?.- 40. Central Nervous System Failure: Neurotrauma Trials.- 41. Stress Gastritis: Is It a Disappearing Disease?.- 42. Gut and the Immune System: Enteral Nutrition and Immunonutrients.- 43. Disseminated Intravascular Coagulation.- 44. Refunctionalization of the Gut.- 45. Liver: Multiple Organ Dysfunction and Failure.- 46. Liver: Hepatic Support and the Bioartificial Liver.- VI Therapeutic Horizons.- 47. Laboratory Markers to Support Early Diagnosis of Infection and Inflammation.- 48. Endotoxin Antagonists.- 49. Blood Purification Therapy to Prevent or Treat MOF.- 50. Antithrombin III and Tissue Factor Pathway Inhibitor: Two Physiologic Protease Inhibitors of the Coagulation System.- 51. Rationale for Glucocorticoid Treatmentin Septic Shock and Unresolving ARDS.- 52. Pathophysiologic and Clinical Importance of Stress-Induced Th1/Th2 T Cell Shifts.- 53. Pathophysiologic and Clinical Role of Interferon-? and Its Release Triggering Cytokines IL-12 and IL-18.- 54. Interleukin-11: Potential Therapeutic Activity in Systemic Inflammatory States.- 55. Minimal Surgical Procedures to Decrease the Stress Response and New Potential Therapeutic Agents.- 56. Wound Healing: Physiology, Clinical Progress, Growth Factors, and the Secret of the Fetus.- 57. Problems with Magic Bullets: Future Trials and Multiagent Therapy.- 58. Maximizing Oxygen Delivery and Consumption: In Whom and for Whom?.- 59. Gut Decontamination: Prevention of Infection and Translocation.- 60. Myocardial Depression: Is It Clinically Relevant?.- 61. Infection: Cause or Result of Organ Failure?.- 62. Hypertonic Solutions.- 63. Blood Substitutes.- 64. Growth Factors G-CSF and GM-CSF: Clinical Options.- 65. Anabolic Effects of Growth Hormone in Critically Ill Patients.- 66. Immunoglobulin Therapy: Where Does It Stand Clinically?.- 67. Horizons in the Anesthetic Care of Injured, Operated, and Stressed Patients.- 68. Integrative Biology and Genetic Variability: MODS’ Next Frontiers.- 69. Are We Making Progress in Preventing and Treating MOF?.- 70. Ethical Considerations of MODS, SIRS, and MOF.- 71. Socioeconomic Impact of Multiple Organ Failure.- 72. Future Directions in the Treatment of SIRS and MODS.- 73. Summary and Overview: What Does the Future Hold?.